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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a fatal motoneuron disease, characterized by progressive weakness, muscle wasting
and death ensuing 3–5 years after diagnosis. The etiology of ALS is complex and therapeutic approaches rely mostly on
transgenic animal models with SOD-1 mutations. Most frequently employed is a mouse line transgenic for SOD-1 (SOD-1 Tg)
that contains a point mutation at amino acid position 93 (G-.A), present in patients suffering from a familial form of
amyotrophic lateral sclerosis. Here we report on a SOD-1 (G93A) Tg mouse line with abnormally delayed onset of disease
and prolonged survival. This phenotype arose spontaneously in our colony of the classic SOD-1 (G93A) line. We found that
the copy number of the SOD-1 transgene was drastically decreased. We established a new breeding colony, the SOD-1
(G93A)
PS line (PS for prolonged survival) where the phenotype is stably inherited for 4 generations now. The mice develop
symptoms at an age of approximately 12 months and die at 15 months of age. The delayed development of disease may
more closely mimic human pathophysiology, and studying drug effects in this model may yield added confidence for
potential efficacy of ALS drug candidates.
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Introduction
Amyotrophic Lateral Sclerfosis (ALS) is an incurable fatal
motoneuron disease, characterized by progressive weakness,
muscle wasting and death ensuing 3–5 years after diagnosis [1].
For the majority of the ALS cases, the disease etiology is sporadic,
but ,10% of ALS patients have a familial form of ALS. Most of
the familial cases are due to mutations within the gene encoding
the superoxide dismutase 1 (SOD-1) protein, an enzyme involved
in the detoxification of reactive oxygen species [2]. Transgenic
animals carrying mutations in the SOD-1 gene have been
generated and they develop similar symptoms that what is
observed in clinic [3]. Among the different animal models, the
most studied one is a mouse line carrying a point mutation in
amino acid position 93 of the SOD-1 protein (G -.A) that have a
life expectancy of 150 days [4]. Previous reports indicate that slight
spontaneous drops in transgene copy number result in a change in
symptoms severity and disease progression [5]. Here, we report on
a novel SOD-1 (G93A) transgenic mouse line with a drastically
reduced copy number of the SOD-1 (G93A) transgene.
Methods
Maintenance of the SOD-1 (G93A) colony
Mice transgenic for the SOD1(G93A) mutation [3] on a
C57BL/6 background (B6.Cg-Tg(SOD1-G93A)1Gur/J strain;
Jackson laboratory, Bar Harbour, Maine) that harbor the high
copy number of the mutant allele human SOD1 were maintained
as a hemizygous line in an SPF-breeding facility (University of
Heidelberg, Interfakulta ¨re Biomedizinische Forschungseinrichtung
(IBF)). The hemizygous line was maintained by mating transgenic
males with C57BL/6 wild-type females.
Assessment of disease progression
Body mass were recorded at regular interval at 9 am. Onset of
weight decrease was defined as a drop of 5% of the mouse
maximal weight. Muscular strength was followed by grip strength
measurements (GS Columbus). Mean of three tests was recorded.
Clinical onset of disease was defined as beginning of gait
impairment, defined as abnormal limb movement in at least one
hind limb. Clinical end stage was defined as inability of the animal
to right itself over a period of 30 s. Animals were sacrificed at that
point. Disease duration was defined as the time in day between the
clinical onset of disease and the clinical end point of disease.
Quantitative PCR
Copy numbers of the SOD-1 transgene were estimated by
quantitative PCR on genomic DNA by comparing SOD-1/
cyclophilin ratios of SOD-1 Tg mice and SOD-1 (G93A)
PS mice.
The following primer sets were used: SOD-1
G93As (GTG TGC
GTG CTG AAG GGC GA), SOD-1
G93Aas (CCA CCT TTG
CCC AAG TCA TCT GC), cyc5 s (ACC CCA CCG TGT TCT
TCG AC), cyc300as (CAT TTG CCA TGG ACA AGA TG),
60uC, 82uC. Amplification conditions were 60uC annealing and
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62uC annealing and 78uC measuring temperature for the SOD-
1
G93A product. Specificity of product was ensured by melting
curve analysis and agarose gel electrophoresis. Relative levels were
derived after normalization to cyclophilin.
Conduct of experiments and statistics
Experiments were performed in a blinded manner with
blindness of all experimenters to genotype identity as long as
possible. Group or pairwise parametric or non-parametric
comparisons were done using JMP 8.01 (SAS Institute) or NCSS
software (NCSS, Kaysville, Utah). Survival and onset data were
analyzed using the logrank test. A p value of ,0.05 was considered
significant. All animal experiments were approved by the ethics
committee of the Regierungspra ¨sidium Karlsruhe, Germany
(referat 35) with the ID approval number AZ 35-9185.81/G-
151/06.
Results
In our breeding colony of SOD-1 (G93A) transgenic mice we
noted absence of typical ALS-like symptoms in a female mouse at
a time point where mice from the original SOD-1 (G93A) line
usually suffer from strong gait impairment and reduced motor
function. Initially we suspected an error in genotyping. Genotyp-
ing was therefore repeated and confirmed that the mouse was
carrying the SOD-1 transgene (Fig. 1a). We bred this mouse to
wild type C57BL/6 mice, and were able to preserve the phenotype
in about 50% of the offspring, consistent with a Mendelian
inheritance pattern. We refer to this mouse and its offspring as the
SOD-1 (G93A)
PS (for prolonged survival) line.
We determined transgene copy number by quantitative PCR on
genomic DNA. The SOD-1 (G93A)
PS line showed a drastic (about
six-fold) drop in their copy number of the SOD-1 transgene when
compared to normal SOD-1 Tg mice (Fig. 1b). The copy number
Figure 1. The SOD-1 (G93A) transgene in the SOD-1 (G93A)
PS line. (A) Genotyping of the SOD-1 (G93A)
PS mouse reveals a characteristic band
from the SOD-1 (G93A) transgene. (B) Copy number of the SOD-1
G93A transgene is reduced in the SOD-1 (G93A)
PS mice by a factor of 6 when
compared to normal SOD-1 (G93A) mice, littermates from the first SOD-1 (G93A)
PS mouse or from newly rederived SOD-1 (G93A) mice (p,0.05).
doi:10.1371/journal.pone.0015445.g001
Figure 2. Weight loss and muscular strength deficit are delayed in the SOD-1 PS line. (A) The SOD-1 (G93A)
PS mice (n=8) have a delayed
onset of weight decrease when compared to the original line (n=17) (p,0.05). (B) Normal SOD-1 Tg mice start with a decrease in muscle strength at
the age of 70 days. SOD-1 (G93A)
PS mice have normal muscular strength until the age of 310 days (p,0.05).
doi:10.1371/journal.pone.0015445.g002
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(G93A)
PS line. According to previous quantification of transgene
copy number [3,6], the SOD-1 (G93A) mice harbours 25 copy of
the SOD-1 (G93A) transgene. We deduce from the PCR
quantification that the SOD-1 (G93A)
PS line harbours 4 copies
of the transgene.
We then systematically studied the phenotype by monitoring
muscular strength, body weight, symptoms progression and
survival (n=8 mice per group (wt littermates, and SOD-1
(G93A)
PS line), n=17 mice from original SOD-1 (G93A) line,
all female)). There are obvious differences in the development of
disease symptoms in the SOD-1 (G93A)
PS line when compared to
the original line. In the SOD-1 (G93A)
PS line, the muscular deficit
and body weight decrease occur later than in the original line
(p,0.05, Fig. 2). Surprisingly, we noted that during the
presymptomatic phase mice from the SOD-1 (G93A)
PS line have
a relative increase in body mass compared to the wild type
littermates (5 g maximal difference, p,0.05). This apparently
counterintuitive finding merits further exploration particularly in
view of reports on metabolic disturbances in mutant SOD-1
transgenic mice. Interestingly, higher food intake was observed in
presymptomatic mice of the SOD-1 (G86R) transgenic line [7].
Regarding the clinical symptoms, substantial differences have
been observed as well (Fig. 3). In the original line, mice develop
tremor in the hindlimbs around 70 day of age, gait impairment
around the age of 110 days, and reach the endpoint of disease at
150 day of age. In the SOD-1 (G93A)
PS line, tremor was
inconsistent and not present in all mice. Gait impairment was
however consistently present and first observable at 380 days of
age. Mice reached the clinical end point of the disease at 418 days
of age (Table 1). We monitored survival through 4 subsequent
generations and found that the life expectancy was equal,
suggesting that the new line is genetically and phenotypically
stable (Table 2). As tremor is not a reliable symptom in the new
line, we defined the disease onset as the first occurrence of gait
impairment at 380 days of age. It is interesting to note that the
disease duration (time between disease onset and disease end
point) is about 42 days and therefore similar between the original
and the PS line (Table 1).
We conclude that the drop in transgene copy number in our
new line led to strong delay of disease onset and extended survival,
but does not prolong disease duration.
Figure 3. Timed data for onset and survival. Given are parameters
for disease onset (A-C), and survival (D) for the SOD-1 (G93A) (n=17)
and SOD-1 (G93A)
PS mice (n=8). (A) Onset of weight decrease was
defined as a drop of 5% of the mouse maximal weight. (B) First
manifestation of symptoms that are linked to gait impairment in terms
of limbs coordination and overall stance, and (C) time to first
manifestation of paresis. (D) End point of the disease, defined as the
inability of the mouse to right itself within 30 seconds.
doi:10.1371/journal.pone.0015445.g003
Table 1. Listed are key characteristics of ALS-like symptoms
in the original SOD-1 (G93A) and in the new SOD-1 (G93A)
PS
line (mean6SEM).
SOD-1 G93A SOD-1 G93A
PS p value
Weight decrease
(days)
138.3563.0 359.468.5 ,0.05
Onset of gait
impairment (days)
109.562.1 380.364.0 ,0.05
Survival (days) 151.565.1 418.6611.9 ,0.05
Disease duration
(days)
42.064.8 41.2269.9 .0.60
doi:10.1371/journal.pone.0015445.t001
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SOD-1 (G93A) transgenic mouse lines with low copy numbers
have been previously described by other groups. The first line
reported is almost as old as the original line [8]. These mice
harbour around 14 to 17 copies of the SOD-1 (G93A) transgene
[9], have a prolonged asymptomatic phase, and a reported survival
between 200 days [10] and 273 days, with a disease duration
(disease onset defined as apparition of motor impairment) of 49
days [11]. The disease duration is comparable to what we report
here (see Table 1). The line described here has however the longest
disease-free interval, the lowest copy number, and longest survival
of all reported lines.
The similar disease duration between the mouse lines is
interesting because it suggests that the transgene number copy
has an influence on the length of the asymptomatic phase but not
on the disease duration. This implies that once the onset of disease
is reached, the disease starts and progresses at a precise pace.
Mouse lines with low transgene copy numbers are therefore
interesting for the study of the asymptomatic phase and factors
that determine disease onset.
The fact that dramatic losses of transgene copies occur in the
SOD1 (G93A) line even after a long time of breeding brings one
issue to mind that is important in pre-clinical drug studies: Control
of copy number. Recently, doubts have been raised as to the
relevance of the SOD-1
G93A mouse line as an animal model of
ALS. These doubts are based on the clinical phase III failure of
several compounds that had beneficial effects in the SOD-1
(G93A) Tg line [12]. Scott and colleagues point out several
problematic points with the SOD1 line [13]. Slight variations in
transgene copy numbers is one of the explanations given for
potentially erroneous results in animal studies, as survival
correlates inversely with the copy number [5]. However, a drop
in copy number is judged to be a rare event, with likely moderate
influence on preclinical results. Apart from small copy number
variations, major losses of copy numbers can happen even after the
long maintenance of the Guerney line. These alterations may
propagate in a colony of transgenic animals if undetected. We
strongly recommend to quantify the copy number for all SOD-1
Tg animals used for breeding and experiments.
Here, we report a mouse line with drastically reduced copy
number of the SOD-1 (G93A) transgene. The mice of this line
exhibit a long asymptomatic phase, reminiscent of the disease
course in ALS patients. Also, SOD-1 (G93A)
PS mice develop the
phenotype at an advanced age that may be more comparable to
human patients where the disease rarely strikes below 40, and is
most commonly seen around the age of 60. Therefore this novel
line may provide a useful additional model for establishing proof-
of-concept for new therapeutic concepts.
As the presymptomatic phase is longer, the SOD-1 (G93A)
PS
mice may also be useful for investigations into the pathophysio-
logical mechanisms taking place before the apparition of clinical
symptoms. Finally, the mice described here may be especially
valuable for testing preventive strategies.
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